Leading Food Peptide Companies: Top Global Manufacturers & Industry Leaders

The Food Peptide Growth-Share Matrix: How GLP-1 Diets Are Reshaping Collagen, Whey, and Plant Peptide Manufacturing

The global food peptide market reached an estimated US$5.13 billion in 2025 and is projected to grow at a 7.8% CAGR to US$7.5 billion by 2031. Animal-based peptides — principally dairy, milk, and fish-derived — hold the largest source-segment position at roughly 50.7% share, while Asia Pacific leads regionally at 34.5% of the market.

What distinguishes this market's 2026 narrative from a year ago is a single, recurring theme across nearly every major supplier's public commentary: GLP-1 weight-management drugs are actively reshaping demand for protein and peptide ingredients. Arla Foods Ingredients, DSM-Firmenich, Cargill, and Darling Ingredients' Rousselot business have all independently cited GLP-1-linked dietary change — the need for concentrated, muscle-preserving protein in smaller portions — as a direct driver of ingredient demand in their most recent 2026 disclosures, a level of cross-company consensus rarely seen this cleanly in a single sourcing category.

This briefing applies the BCG growth-share framework to eleven named manufacturers spanning the value chain — global ingredient majors (Kerry Group, ADM, Cargill, Roquette Frères, DSM-Firmenich), specialist collagen-peptide producers (GELITA AG, Rousselot, Darling Ingredients, PB Leiner), and dairy/gelatin specialists (Arla Foods Ingredients, Nitta Gelatin) — using only what each company has itself disclosed in 2026 earnings releases, investor communications, and public statements.

Market Sizing Snapshot, 2026–2031

Source: Global Food Peptide Market Strategic Research Report, Market Research Reports Inc., benchmarked against Global Market Insights' independently published third-party estimate.

The Growth-Share Lens, Applied to Food Peptides

Three ingredient categories now define competitive position across the eleven majors profiled:

• Premium collagen and targeted-health peptides — the fastest-growing, highest-margin category, where Darling Ingredients itself discloses that collagen carries 2.5–3x the margin of commodity gelatin, and targeted bioactive ingredients like Nextida carry 7–11x.
• Dairy-derived whey and bioactive peptides — a category now explicitly benefiting from GLP-1-linked demand for high-protein, muscle-preserving nutrition in smaller serving formats.
• Plant-based and legacy commodity peptides (gelatin, bulk pea/soy protein) — a maturer, more price-sensitive segment that continues to fund innovation in the categories above.

Company-by-Company Positioning

Kerry Group — the broad-base Cash Cow investing into high-protein innovation

Kerry reported H1 2026 revenue of €3.34 billion, down from €3.46 billion a year earlier on unfavorable currency translation, but with EBITDA rising slightly to €558 million and volume growth remaining significantly ahead of underlying food and beverage end markets. Management explicitly cited customer innovation activity orientated toward "higher protein, proactive health, and new format options" as a key growth driver, alongside continued development of Kerry's Taste and Biotechnology Solutions capabilities, and reaffirmed constant-currency adjusted EPS guidance of 6–10% growth for 2026.

MRR Take: Kerry's core taste and nutrition base functions as a Cash Cow — large, resilient, and currency-exposed but fundamentally stable — while its high-protein and biotechnology solutions push represents a Question Mark the company is deliberately steering resources toward as end-market protein demand accelerates.

ADM — the diversified Cash Cow where Nutrition profit is quietly outrunning revenue

ADM's Q2 2026 revenue reached $22.68 billion, with Nutrition segment revenue down 5% year-over-year to $1.9 billion, yet Nutrition operating profit rose 51% to $172 million, driven primarily by growth in Flavors and progress in Specialty Ingredients. Human Nutrition operating profit specifically rose 51% to $139 million. Management raised full-year 2026 adjusted EPS guidance to $5.15–$5.60, citing biofuels strength alongside Nutrition momentum.

MRR Take: ADM's Nutrition segment as a whole is a Cash Cow with a Star pocket — overall segment revenue is flat-to-declining, but the Flavors and Specialty Ingredients sub-segments driving the 51% profit jump are the clear high-margin growth engine management is now prioritizing.

Cargill — the private ingredients giant repositioning around GLP-1-adjacent nutrition

Cargill, privately held and reporting no public earnings, has nonetheless been explicit in 2026 trade commentary about its strategic direction: at Vitafoods Europe 2026, the company showcased active-nutrition concepts addressing "gut health, reduced sugar, and GLP-1-driven dietary changes," including high-protein shakes and portion-controlled, bite-sized formats. Cargill's bioindustrial division also supplies fermentation-derived peptide ingredients (including its FermaBoost line) alongside its broader protein hydrolysate portfolio spanning food, animal nutrition, and industrial applications.

MRR Take: Cargill's diversified bioindustrial and protein-ingredient base is a broad Cash Cow; its GLP-1-companion nutrition concept work represents an emerging Question Mark the company is actively prototyping toward, without yet disclosing dedicated financial results for the category.

Roquette Frères — the plant-peptide specialist navigating a more commoditized Question Mark

Roquette, privately held, continued to expand its NUTRALYS plant-protein and peptide portfolio in 2026, launching NUTRALYS Pea 850F — a clean-tasting, high-solubility pea protein isolate designed for ready-to-mix and ready-to-drink applications — in February 2026. Independent market analysis identifies Roquette as a leader in pharmaceutical-grade pea peptide hydrolysates, commanding premium pricing through enzymatic specificity, though the broader pea protein category remains subject to commodity-style price volatility tied to Canadian prairie harvest yields.

MRR Take: Roquette's plant-peptide business is a genuine Question Mark — the underlying market (pea protein peptides, ~8.5% CAGR through 2035) is growing steadily, but Roquette's position sits between a defensible pharmaceutical-grade premium tier and a more commoditized bulk isolate market that is not yet clearly a Star.

DSM-Firmenich — the reshaping Cash Cow explicitly targeting GLP-1-linked reformulation

DSM-Firmenich reported H1 2026 continuing-operations sales of €4.66 billion, up 5% like-for-like (accelerating to 6% in Q2), with its Taste, Texture & Health division posting 6% organic growth to €843 million in Q2 alone. Most notably, the company's Health, Nutrition & Care segment disclosed it is "developing dairy solutions addressing demand for high-protein and GLP-1-related food choices" as a named growth investment area, alongside expanding HMO production for early-life nutrition and continued momentum in algae-derived Life's Omega-3 lipids. The company is simultaneously divesting its Animal Nutrition & Health business (expected to close end of 2026) to sharpen its consumer-health focus.

MRR Take: DSM-Firmenich's Taste, Texture & Health and Health, Nutrition & Care divisions form the company's Star cluster post-divestment, with the explicit GLP-1-linked dairy solutions initiative the clearest, most directly-named Star investment among all eleven companies profiled.

GELITA AG — the independent collagen-peptide specialist scaling targeted health applications

GELITA, privately held, has continued expanding beyond traditional beauty-focused collagen applications into mobility, connective tissue health, muscle recovery, and healthy aging, with new clinical validation for its BODYBALANCE Bioactive Collagen Peptides in sports nutrition. The company also increased its ownership stake in joint venture SelJel toward near-full ownership and continues developing biomedical-grade, animal-free recombinant collagen proteins.

MRR Take: GELITA's targeted-health collagen peptide portfolio is a clear Star — independent of the Darling/Tessenderlo consolidation reshaping its two largest rivals, GELITA is scaling the same high-margin, science-backed collagen applications that define this market's fastest-growing segment.

Rousselot (Darling Ingredients) — the Star at the center of a landmark industry consolidation

Rousselot, Darling Ingredients' collagen and gelatin business, is the majority driver of Darling's Food segment, which management describes as offering "significant opportunity to enhance earnings and cash flow through product mix optimization" — collagen products carry 2.5–3x gelatin's margin, and Rousselot's targeted Nextida ingredients carry 7–11x. Most significantly, Rousselot has showcased Nextida GC, positioned explicitly for metabolic health and weight management — direct GLP-1-adjacent positioning — while Darling and Tessenderlo Group finalize their agreement to merge Rousselot with PB Leiner into a new ~$1.5 billion-revenue collagen company (Darling holding 85%, Tessenderlo 15%), expected to close in 2026.

MRR Take: Rousselot is unambiguously a Star — Darling's own disclosed margin math shows collagen and targeted-health ingredients are the company's highest-return products, and the pending PB Leiner combination is a direct, capital-light move to consolidate Star-segment capacity and reach nearly 40% combined European collagen peptide share.

Darling Ingredients — the diversified Cash Cow funding its Star through consolidation

Darling Ingredients reported Q2 2026 net sales of $1.7 billion and combined adjusted EBITDA of $742 million, up sharply from $250 million a year earlier, driven by strong fat and protein prices and outstanding performance at its Diamond Green Diesel renewable fuels joint venture. Within the Food segment, management confirmed continued growth in collagen sales, driven by both rising customer demand and the emergence of new applications across food, nutrition, and health — with collagen increasingly positioned as a complement to whey protein as whey prices rise.

MRR Take: Darling's core rendering and fuel businesses remain a large, diversified Cash Cow; the company's explicit strategic language — prioritizing collagen mix shift, organic collagen capacity additions in China and Paraguay, and the PB Leiner combination — confirms Rousselot as the Star the broader Cash Cow is now directly funding.

PB Leiner (Tessenderlo Group) — the third-largest European producer being absorbed into a Star

PB Leiner, Tessenderlo Group's gelatin and collagen peptide business, has been confirmed by German antitrust authority Bundeskartellamt as currently the third-largest gelatin and collagen peptide producer in Europe. Rather than continuing to operate independently, PB Leiner is being combined with Rousselot into a new jointly-owned entity — with Tessenderlo CEO Luc Tack describing the move as enabling both companies to "benefit from each other by sharing technology expertise" — creating a combined 200,000-metric-ton gelatin and collagen production network across 22 facilities.

MRR Take: PB Leiner's standalone position was a Cash Cow with Star potential it lacked the scale to fully capture alone; folded into the new Rousselot/PB Leiner combination, that capacity becomes part of a single, larger Star entity — a direct example of industry consolidation converting fragmented share into a genuine growth leader.

Arla Foods Ingredients — the whey-peptide Star with the most explicit GLP-1 linkage in the sector

Arla Foods Ingredients delivered H1 2026 revenue growth of 19.3% to €867 million, driven by higher whey protein prices reflecting "continued strength in whey-based ingredients demand linked to health and nutrition trends, including the impact of GLP-1 diets," alongside 5.7% volume growth in its value-add segment (now 84.6% of AFI's mix). At the group level, parent cooperative Arla Foods reported H1 2026 revenue of €7.6 billion and explicitly raised guidance following its merger with DMK Group, while separately targeting "GLP-1 companion nutrition" at Vitafoods Europe 2026 with high-protein, nutrient-dense fermented and yogurt-format concepts.

MRR Take: Arla Foods Ingredients is the single clearest Star in this entire matrix — no other company profiled ties GLP-1-linked demand this directly and quantifiably to double-digit ingredient revenue growth, making its whey-based bioactive peptide portfolio the sector's leading proof point for the category's broader thesis.

Nitta Gelatin — the specialist scaling targeted collagen peptides from a smaller base

Nitta Gelatin's Japan-listed parent carries a trailing-twelve-month revenue of approximately $252 million, while its Indian joint venture, Nitta Gelatin India, posted Q4 FY26 net sales up 25.2% year-over-year to ₹161.7 crores, marking its seventh consecutive quarter of year-over-year revenue growth, with operating margin expanding more than 1,000 basis points to 28.07%. The company's Wellnex collagen peptide range includes formulations specifically targeted at diabetes management alongside bone, joint, and beauty applications.

MRR Take: Nitta Gelatin is a Question Mark with clear Star momentum — its consistent multi-quarter revenue and margin expansion, anchored by targeted-health collagen peptides including diabetes-management formulations, mirrors the same high-margin trajectory driving Rousselot and GELITA, but from a considerably smaller global revenue base.

Consolidated Growth-Share Matrix — Food Peptide Manufacturers, 2026

As with the pharmaceutical manufacturing value chain, the absence of a populated Dogs quadrant here reflects a market in active reinvention: every company profiled is either directly linking its ingredient portfolio to the GLP-1-driven protein demand shift or is in the process of consolidating scale (Rousselot/PB Leiner) to compete more effectively in it.

Strategic Imperatives for 2026–2031

1. GLP-1-linked protein demand is now a named, quantified line item — not a speculative trend. Arla's 19.3% ingredient revenue growth and DSM-Firmenich's explicit "GLP-1-related food choices" product development language both demonstrate that this driver has moved from industry conference talking point to disclosed financial driver within a single year.
2. Consolidation is concentrating collagen-peptide share fast. The Rousselot/PB Leiner combination alone will control close to 40% of European collagen peptide share per German antitrust review — a scale shift that smaller independents like GELITA and Nitta Gelatin will need to answer with continued innovation-led differentiation rather than scale competition.
3. Margin, not just volume, is the real strategic prize. Darling's own disclosed figures — collagen at 2.5–3x gelatin margin, targeted ingredients at 7–11x — make explicit what most of this market's participants are quietly executing: shifting mix toward premium, targeted-health peptides is now a stated corporate priority, not an incidental byproduct of demand.
4. "GLP-1 companion nutrition" is emerging as its own product category. Both Cargill and Arla Foods Ingredients used near-identical language at Vitafoods Europe 2026 to describe ingredient systems purpose-built for the post-GLP-1 and appetite-aware nutrition occasion — suggesting the category is coalescing into a defined commercial segment rather than remaining a loose collection of high-protein reformulations.

Outlook

With the underlying market forecast to reach $7.5 billion by 2031, and GLP-1-linked demand now cited as a direct growth driver by companies spanning dairy, collagen, and diversified ingredient majors alike, the central strategic question for 2026–2031 is which companies convert this demand signal into durable, defensible share fastest. On the disclosed evidence, Arla Foods Ingredients has the clearest quantified proof point today, the Rousselot/PB Leiner combination represents the most consequential structural share shift, and DSM-Firmenich's explicit product-development commitments suggest the diversified ingredient majors are moving to compete directly rather than cede the category to specialists.

This analysis draws on company-reported earnings releases, investor presentations, trade-press interviews, and public regulatory filings from Kerry Group, ADM, Cargill, Roquette Frères, DSM-Firmenich, GELITA AG, Rousselot, Darling Ingredients, PB Leiner, Arla Foods Ingredients, and Nitta Gelatin, current through September 2026, together with the market-sizing framework of the Global Food Peptide Market Strategic Research Report.